Cipla Limited
CIPLA
Rangering i aksjer
#1810
Cipla Limited, along with its associated entities, operates as a global... Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
Aksjekurs
$14.61
Sist synkronisert: 2026-10-19
Markedsverdi
$11.81B
Endring (1 dag)
-0.11%
Endring (1 år)
-21.65%
Land
IN
Handel Cipla Limited (CIPLA)
Kategori
Healthcare
P/S-forhold for Cipla Limited (CIPLA)
P/S-forhold per October 2026 TTM: 3.82
Ifølge Cipla Limited sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 3.82. Ved slutten av 2024 hadde selskapet et P/S-forhold på 4.74.
P/S-historikk for Cipla Limited fra 2004 til 2026
P/S-forhold ved hvert års slutt
| År | P/S-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 3.82 | -10.80% |
| 2025 | 4.28 | -9.65% |
| 2024 | 4.74 | 47.08% |
| 2023 | 3.22 | -14.85% |
| 2022 | 3.78 | 10.05% |
| 2021 | 3.44 | 72.27% |
| 2020 | 2.00 | -23.06% |
| 2019 | 2.59 | -15.52% |
| 2018 | 3.07 | -7.69% |
| 2017 | 3.33 | 9.59% |
| 2016 | 3.03 | -39.81% |
| 2015 | 5.04 | 86.12% |
| 2014 | 2.71 | -27.40% |
| 2013 | 3.73 | 6.94% |
| 2012 | 3.49 | -98.05% |
| 2011 | 179.33 | 3,495.17% |
| 2010 | 4.99 | 44.67% |
| 2009 | 3.45 | -19.14% |
| 2008 | 4.26 | -20.21% |
| 2007 | 5.34 | -22.03% |
| 2006 | 6.85 | 94.90% |
| 2005 | 3.52 | -7.98% |
| 2004 | 3.82 | 0.00% |
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap | P/S-forhold | Forskjell i P/S-forhold | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 7.06 | 84.88% |
IN
|
